Skip to content

The Effects of a Pre-packaged, Portion Controlled Meal Plan on Type 2 Diabetes and Glycemic Control: A Comparison Study

The Effects of a Pre-packaged, Portion Controlled Meal Plan on Type 2 Diabetes and Glycemic Control: A Comparison Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01260337
Enrollment
100
Registered
2010-12-15
Start date
2010-03-31
Completion date
2011-08-31
Last updated
2013-07-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity

Keywords

Weight loss, Type 2 Diabetes, Behavior Modification, portion control

Brief summary

The purpose of this research study to find out whether a pre-packaged, portion controlled diet with a group behavior modification program or group diabetes support and education, is a safe and effective way for people with type 2 diabetes to lose weight and manage their diabetes.

Detailed description

Eligible volunteers are randomly assigned to a treatment group consisting of a pre-packaged, portion controlled meal plan plus a group behavior modification program or to a control group that consists of a group diabetes support and education (DSE) program. Random assignment will be stratified by whether or not a subject is taking insulin at baseline, which will be included as a covariate in all subsequent analyses. Treatment assignments are unmasked. At the end of 24 weeks both groups will have completed 9 group sessions (weeks 0, 1, 2, 4, 8, 12, 16, 20 and 24). At week 16, each participant will meet individually with the study physician to review their progress to date. These meetings will take place at the week 16 group visit. The PCD program is aimed at achieving and maintaining a decrease in weight and providing a group behavior modification program from 0-24 weeks. The DSE program is aimed at providing diabetes support and education from weeks 0-24. A Certified Diabetes Educator (CDE) will review the effects of diet and weight loss, exercise, and medications on blood glucose levels among all participants at the individual session before any changes in dietary intake or exercise are prescribed. Participants will be counseled on strategies to prevent hypoglycemia and will be given a blood glucose meter and strips and instructed to measure their blood glucose at least two times per day while participating in the study. In addition, the causes, symptoms and treatment of hypoglycemia will be reviewed including when to contact their health care provider.

Interventions

BEHAVIORALPortion controlled diet

Participants learn skills for changing nutritional and lifestyle habits and diabetes management follow a program that includes eating a pre-packaged, portion controlled meal for weight loss in addition to attending the behavior modification groups

The DSE groups will consist of educational sessions offered for diabetes support and education which will include sessions on diet/nutrition, exercise, foot care and living with diabetes.

Sponsors

Nutrisystem, Inc.
CollaboratorINDUSTRY
University of Pennsylvania
CollaboratorOTHER
Temple University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
21 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

1. Type 2 diabetic men and non-pregnant or non-lactating women between the ages of 21 to 75 2. BMI ≥ 25 and ≤ 50 3. Subjects must be willing to comply with all study-related procedures 4. Participant with screening HbA1C ≥ 6.5 and \<12.0.

Exclusion criteria

1. Use of Byetta (exenatide) or Symlin (pramlintide acetate) for diabetic control\< 6 months. Participants must be stable on all other medications for at least 3 months for inclusion. If a participant is on a medication for less than 3 months and the study physician determines the medications will not affect the study outcomes (weight, glycemic control, etc), they can be enrolled (excluding hypertension or cholesterol medications). 2. BMI ≤24.9 or ≥ 50.1 3. Participation in another formal weight loss program within last 6 months 4. Weight loss \> 5 kg during the last 6 months 5. Participation in Diabetes Support and Education Program or other formal diabetes education program within last 6 months 6. Uncontrolled hypertension (systolic blood pressure \> 180 or diastolic blood pressure \> 100 mmHg). Participants on medication treating hypertension for at least three months are allowable. 7. Known atherosclerotic cardiovascular disease 8. History of congestive heart failure 9. History of a non-skin malignancy within the previous 5 years 10. Any major active rheumatologic, pulmonary, hepatic, renal, dermatologic disease or inflammatory condition 11. History of testing HIV positive 12. History of alcohol or drug abuse 13. Weight-loss inducing medications or dietary supplements within 3 months prior to enrollment. 14. Participation in any weight loss study or investigational drug study within 6 weeks prior to the screening 15. Serious or unstable medical or psychological conditions that, in the opinion of the investigator, would compromise the subject's safety or successful participation in the study. 16. Participants taking anti-depressants (SSRI's are allowed except for bupropion \[Wellbutrin\]) , mood stabilizers, anti-psychotics, and psychiatric medications treating any mood, psychological or psychiatric condition. Refer to Appendix 1 for medication exclusion list. 17. Participants with screening triglycerides above 500 mg 18. Uncontrolled Dyslipidemia as defined by screening LDL cholesterol of ≥ 160 mg/dL. Participants on medication treating dyslipidemia for at least 3 months are allowable. 19. Any female who tests positive on a urine pregnancy test or who reports being pregnant at screening 20. Gastrointestinal Disorders (gallbladder disease, Crohn's disease, Irritable bowel syndrome, and any GI disease that affects malabsorption). 21. An allergy to certain foods that cannot be avoided due to the nature of the packaged foods such as, but not limited to nuts, dairy, gluten, etc. 22. Non-medical related dietary restrictions, such as vegetarians 23. Neuropathy that interferes with exercise. 24. Smoking or tobacco use 25. Previous weight loss surgery.

Design outcomes

Primary

MeasureTime frameDescription
Change in weight at 3 and 6 monthsBaseline, 3 & 6 monthsAssess the effects of a pre-packaged, portion controlled meal plan on weight loss in overweight and obese patients with type 2 diabetes.

Secondary

MeasureTime frameDescription
Change in HbA1C at 3 and 6 monthsBaseline, 3 & 6 MonthAssess the effects of a pre-packaged, portion controlled meal plan on glycemic control in overweight and obese patients with type 2 diabetes.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026